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ABSTRACT
The clinical manifestations of hepatitis B viral infection (HBV) include chronic 
hepatitis B (CHB), liver cirrhosis (LC) and hepatocellular carcinoma (HCC). The 
contribution of negative regulator suppressor of cytokine signaling-3 (SOCS3) 
promoter variants in HBV disease and SOCS3 hypermethylation in tumor tissues 
were investigated. The SOCS3 promoter region was screened for polymorphisms in 
878 HBV patients and in 272 healthy individuals. SOCS3 promoter methylation was 
examined by bisulfite sequencing. SOCS3 mRNA expression was quantified in 37 tumor 
and adjacent non-tumor liver tissue specimens. The minor allele rs12953258A was 
associated with increased susceptibility to HBV infection (OR=1.3, 95%CI=1.1-1.6, 
adjusted P=0.03). The minor allele rs111033850C and rs12953258A were observed in 
increased frequencies in HCC and LC patients compared to CHB patients (HCC: OR=1.7, 
95%CI=1.1-2.9, adjusted P=0.046; LC: OR=1.4, 95%CI=1.1-1.9, adjusted P=0.017, 
respectively). HBV patients with rs111033850CC major genotype had decreased viral 
load (P=0.034), whereas the rs12953258AA major genotype contributed towards 
increased viral load (P=0.029). Tumor tissues revealed increased hypermethylation 
compared to adjacent non-tumor tissues (OR=5.4; 95%CI= 1.9-17.1; P=0.001). 
Increased SOCS3 expression was observed in HBV infested tumor tissues than non-
HBV related tumor tissues (P=0.0048). SOCS3 promoter hypermethylation was 
associated with relatively low mRNA expression in tumor tissues (P=0.0023). In 
conclusion, SOCS3 promoter variants are associated with HBV susceptibility and 
SOCS3 hypermethylation stimulates HCC development.
INTRODUCTION
Hepatitis B virus (HBV) infection is a major health 
problem affecting approximately two billion people 
worldwide. Approximately 240 million individuals are 
chronically infected with 780,000 annually reported 
deaths due to HBV infection [1]. HBV infection causes a 
wide spectrum of clinical manifestations of liver diseases. 
Besides asymptomatic carriers, HBV causes chronic 
hepatitis B (CHB), liver cirrhosis (LC) and hepatocellular 
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carcinoma (HCC). The five-year cumulative risk for the 
development of HBV-related LC ranges between 10% and 
20% [2]. In addition, chronic HBV infection accounts for 
50% of all HCC cases and most HCC cases (70%-80%) 
occur in patients with HBV-related LC [3].
During the course of HBV infection, the mechanism 
of liver injury is dependent on the host immune responses 
[4]. The innate immune responses play a major role in 
suppression of viral replication and in inflammatory 
activity during the early stage of HBV infection. These 
responses include the secretion of interferons (IFNs) 
and cytokines, which are regulated by Janus kinase/
Signal Transducer and Activator of Transcription (JAK/
STAT) signaling [5, 6] and involvement of JAK/STAT 
pathway in HBV infection had been well documented 
[7, 8]. Suppressors of cytokine signaling (SOCS) 
family proteins (CISH and SOCS1 to SOCS7) belong 
to a classical negative feedback system that regulates 
cytokine transduction via JAK/STAT signaling pathway 
[9]. Of these SOCS family, SOCS3 is a key regulator of 
interleukin (IL)-6 and IL-10, which are activated by Toll-
like receptor stimulation. SOCS3 can inhibit the process 
of cell proliferation and cell survival through inhibition of 
STAT3 activation [6, 10]. STAT3, an oncogene, is largely 
correlated with NF-kβ activation [11, 12]. The activation 
of STAT3 by cytokines (e.g. IL-6 and IL-22) mediated 
by JAK/STAT signaling pathway was shown earlier to 
induce inflammation and subsequent carcinogenesis [10–
12]. SOCS3 functionally suppresses STAT3 activation 
and negatively regulate tumor development. Therefore, 
SOCS3 is a vital regulator of several diseases including 
atopic, autoimmune and infectious diseases, inflammation, 
and cancer development [13, 14].
SOCS3 overexpression has been shown in the liver 
tissue of CHB patients and is associated with the severity 
of inflammation suggesting that JAK/STAT signaling 
pathway is dysregulated in HBV-infected hepatocytes 
[15]. The hypermethylation in the CpG (5'-Cytosine-
phosphate-Guanine-3') islands of the SOCS3 promoter 
can be a prognostic indicator in cancer development [16]. 
In addition, SOCS3 expression is further influenced by 
SOCS3 polymorphisms, especially in the SOCS3 promoter. 
To date, SOCS3 polymorphisms were documented in 
several diseases including HCV infection and colorectal 
cancer [14, 17–20]. However, there are so far no 
available data on association of SOCS3 promoter variants 
with susceptibility to HBV infection and the clinical 
course of HBV-related liver diseases. In addition, the 
involvement of epigenetics during the clinical course of 
HBV infection needs to be studied. Therefore, this study 
aims to investigate whether SOCS3 promoter variants are 
associated with HBV infection and HBV-related liver 
diseases and to investigate the hypermethylation in the 
SOCS3 promoter region and corresponding SOCS3 mRNA 
expression in HBV-related HCC.
RESULTS
Baseline characteristics of study participants
The baseline characteristics of the 878 HBV-
infected patients and 272 healthy controls (HC) are 
shown in Table 1. Most HBV patients and HCs were male 
(86% and 66%, respectively). The median age of patients 
increased according to the clinical progression of the liver 
disease. HCs were younger than patient groups (P<0.05). 
The levels of liver enzymes ALT, AST and HBV loads 
were higher in CHB patients compared to other subgroups 
(P<0.01). As expected, albumin and prothrombin levels 
and platelet counts were lower in LC patients compared 
to the other patient groups (P<0.001). AFP levels were 
higher in HCC patients compared to CHB and LC patients 
(P<0.001). The clinical profile of the 37 HCC patients who 
underwent surgery and corresponding data of their liver 
specimens are described in Table 2. Most patients were 
male (89%) and were between 40-60 years of age (73%). 
The HCC patients were in early and/or at intermediate 
stage of liver cancer according to the Barcelona clinic liver 
cancer (BCLC) staging criteria (stage A: 70% and stage 
B: 30%). All the patients were Child-Pugh class A group 
according to Child-Pugh classification. HBV was the 
common etiology of the liver cancer in this study (46%), 
while 8% suffered from HCV infection, and 46% showed 
non-HBV/non-HCV related HCC.
SOCS3 promoter variants and HBV-related liver 
diseases
The genotype and allele frequencies of two SOCS3 
promoter SNPs (rs111033850T/C, rs12953258C/A) 
in clinically classified 878 HBV patients and 272 HCs 
are described in Table 3 and Supplementary Table 2. 
The analyzed SNPs in healthy controls were in Hardy-
Weinberg equilibrium (P>0.05). We compared the 
genotype and allele frequencies between HBV patients 
and HCs. We observed that heterozygous genotype 
rs111033850TC and minor allele rs111033850C were 
less frequent in HBV patients compared to HCs (OR=0.4, 
95%CI=0.3-0.6, adjusted P<0.0001 and OR=0.6, 
95%CI=0.4-0.8, adjusted P<0.0001; respectively). In 
contrast, the homozygous genotype rs12953258AA and 
the minor allele rs12953258A were more frequent in 
patients compared to HCs (OR=2.0, 95%CI=1.3-3.2, 
adjusted P<0.0001 and OR=1.3, 95%CI=1.1-1.6, adjusted 
P=0.03; respectively). A similar trend was observed for 
the SNP rs111033850T/C in the dominant genetic model 
and for the SNP rs12953258C/A in the recessive genetic 
model. These results indicated that the rs111033850TC 
contributes to a decreased risk of HBV infection while 
the genotype rs12953258AA contributes to increased 
susceptibility to HBV infection.
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Subsequently, we compared the genotype and 
allele frequencies between different subgroups of HBV 
patients. The genotype rs12953258AA was significantly 
more frequent in LC patients compared to CHB patients 
(OR=1.7, 95%CI=1.02-2.8; adjusted P=0.036). The 
genotype rs111033850TC was also significantly more 
frequent in LC, HCC and HCC+LC groups compared 
to CHB patients (LC vs. CHB: OR=2.6, 95%CI=1.4-
5.0, adjusted P=0.002; HCC vs. CHB: OR=2.6, 
95%CI=1.3-5.0, adjusted P=0.005; LC+HCC vs. 
CHB: OR=2.0, 95%CI=1-4.4, adjusted P=0.048). The 
alleles rs111033850C and rs12953258A were more 
frequent in HCC and in LC patients compared to 
CHB patients, respectively (OR=1.7, 95%CI=1.1-2.9, 
adjusted P=0.046 and OR=1.4, 95%CI=1.1-1.9, adjusted 
P=0.017).
We also observed the gene dose effect of the 
allele rs111033850C when compared CHB with HCC 
and HCC+LC groups (P for trend =0.046 and 0.026, 
respectively). This indicate that the allele rs111033850C 
was associated with an increased risk of HCC and that the 
allele rs12953258A was associated an increased risk of 
LC in CHB patients. There were no significant differences 
when comparing the genotype and allele frequencies of the 
two SOCS3 SNPs in LC and HCC groups with HCC+LC 
group.
Table 1: Clinical profiles of 878 HBV-infected patients and 272 healthy controls
Characteristics CHB (n=212) LC (n=243) HCC (n=220) LC + HCC (n=203) HC (n= 272)
Age (years) 43 [18-82] 55 [18-84] 55 [18-81] 50 [19-81] 36 [18-69] ‡α
Male (%) 74 84.4 92.7 94.1 66 †α
Child-Pugh 
classification (n)
Child A NA 117/236 101/173 93/164 NA
Child B NA 81/236 56/173 52/164 NA
Child C NA 38/236 16/173 19/164 NA
Missing NA 7 47 39 NA
Clinical 
parameters
AST (IU/L) 72 [15-3253] ‡β 52 [15-1221] 50 [17-2158] 49 [21-737] NR
ALT (IU/L) 69 [9-3382] ‡β 46 [8-1426] 46 [10-832] 44 [10-1095] NR
Total bilirubin 
(µmol/l) 17 [8-788] 29 [3-752] 14 [5-235] 22 [7-419] NR
Direct bilirubin 
(µmol/l) 7 [1-472] 12 [1-450] 5 [1.2-167] 8 [1-214] NR
Albumin (g/L) 42 [23-48] 30 [20-47]‡β 39 [27-49] 38 [23-47] NR
Prothrombin  
(% of standard) 87 [30-180] 53.5 [15-101]
§β 80 [31-115] 74 [19.6-118] NR












Protein (IU/L) 4.3 [1.5-300] 7.4 [1.2-400] 196 [1.1- 438] 
§β 168 [1.6-489] §β NR
Abbreviations: CHB: chronic hepatitis B; LC: liver cirrhosis; HCC: hepatocellular carcinoma; HC: healthy control; PLT: 
platelets. AST and ALT: aspartate and alanine amino transferase; IU: international unit; NR: Normal range, NA: not 
applicable. Values given are medians and range. P values were calculated by student's t-test, Fisher exact test, and Mann-
Whitney- Wilcoxon test where appropriate. (†) P<0.05, (‡) P<0.01 and (§) P<0.001. (α) for comparison with LC, HCC and 
LC+HCC group; (β) for comparison with all other groups.
Oncotarget4www.impactjournals.com/oncotarget
SOCS3 promoter haplotypes and HBV-related 
liver diseases
The haplotypes were reconstructed based on the 
two SNPs (rs111033850T/C, rs12953258C/A) and the 
frequencies were presented in Table 4. Haplotype CC was 
found more frequently in HCs compared to HBV patients 
(OR=0.5, 95%CI=0.4-0.75, adjusted P=0.001) indicating 
that this haplotype contributes to a decreased risk of HBV 
infection. We further compared haplotype frequencies 
between different subgroups of HBV patients and 
observed that the frequencies of haplotypes TA and CC 
were significantly higher in LC, HCC and patients with 
both LC and HCC compared to CHB patients (P<0.01) 
(Table 4). This result indicates that the haplotypes TA 
and CC contribute to an increased risk of progression to 
Table 2: Characteristics of 37 HCC patients
Characteristics n (%)
Age (years)
< 40 4/37 (10.8)
40 - 60 27/37 (73)









Child A 37/37 (100)
BCLC staging Classification
Stage A 26/37 (70.3)
Stage B 11/37 (29.7)
Stage C and D 0/ 37 (0)
Clinical parameters Median (Range)
AFP (IU/ml) 240 [4.6 - 300]
HBV-DNA NA
PLT (103/ml) 211 [153 - 461]
AST (IU/ml) 52 [21 - 415]
ALT (IU/ml) 66.5 [17 - 242]
Total Bilirubin (µmol/l) 27.8 [8.9 - 315]
Direct Bilirubin (µmol/l) 6.7 [1 - 178]
Prothrombin (% of standard) 93 [75 - 125]
Protein (g/l) 73 [62 - 78]
Allbumin (g/l) 40 [32 - 48]
Abbreviations: BCLC: Barcelona Clinic Liver Cancer; HCC: hepatocellular carcinoma; AFP: Alpha feto protein; PLT: 
platelets; AST and ALT: aspartate and alanine amino transferase; IU: international unit; NA: not applicable.
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n (%) Cases vs. HC LC vs. CHB HCC vs. CHB HCC+LC vs. CHB












TT 190 (89.6) 198 (81.5) 178 (80.9) 162 (79.8) 191 (70.3) Reference Reference Reference Reference
TC 16 (7.5) 43 (17.7) 36 (16.4) 35 (17.2) 76 (27.9) 0.4 (0.3-0.6) <0.0001 2.6 (1.4-5.0) 0.002 2.6 (1.3-5.0) 0.005 2.0 (1- 4.4) 0.048
CC 6 (2.9) 2 (0.8) 6 (2.7) 6 (3.0) 5 (1.8) 1.1 (0.4 -3.0) 0.89 0.4 (0.1-2.0) 0.2 0.9 (0.2-3.1) 0.8 1.2 (0.3 - 5.3) 0.8
P for trend 1.99 0.12 0.046 0.026
Allele
T 396 (93.4) 439 (90.3) 392 (89) 359 (88.4) 458 (84.2) Reference Reference Reference Reference
C 28 (6.6) 47 (9.7) 48 (11) 47 (11.6) 86 (15.8) 0.6 (0.4-0.8) <0.0001 1.6 (0.9-2.6) 0.07 1.7 (1.1-2.9) 0.046 1.7 (0.9-3.0) 0.09
Dominant
TT 190 (89.6) 198 (81.5) 178 (80.9) 162 (79.8) 191 (70.3) Reference Reference Reference Reference
TC & CC 22 (10.4) 45 (18.5) 42 (19.1) 41 (20.2) 81 (29.7) 0.5 (0.3-0.7) <0.0001 2.0 (1.1-3.7) 0.014 2.0 (1.1-3.8) 0.017 1.9 (1.1-3.7) 0.046
Recessive
TT & TC 206 (97.2) 241 (99.2) 214 (97.3) 197 (79.8) 267 (98.2) Reference Reference Reference Reference
CC 6 (2.9) 2 (0.8) 6 (2.7) 6 (3.0) 5 (1.8) 1.3 (0.5-3.7) 0.64 0.3 (0.1-1.8) 0.2 0.8 (0.2-2.8) 0.7 1.1 (0.3-5.3) 0.8
P for trend 0.058 0.059 0.55 0.33
rs12953258
CC 94 (44.3) 88 (36.2) 86 (39.1) 75 (36.9) 101 (37.1) Reference Reference Reference Reference
AC 72 (34) 88 (36.2) 88 (40) 84 (41.4) 140 (51.5) 0.7 (0.5-0.98) <0.0001 1.3 (0.8-2.0) 0.27 1.34 (0.8-2.2) 0.21 1.4 (0.8-2.4) 0.22
AA 46 (21.7) 67 (27.6) 46 (20.9) 44 (21.7) 31 (11.4) 2.0 (1.3-3.2) <0.0001 1.7 (1.02-2.8) 0.036 1.0 (0.6-1.7) 0.96 1.4 (0.7-2.7) 0.26
Allele
C 260 (61.3) 264 (54.3) 260 (59.1) 172 (42.4) 342 (62.9) Reference Reference Reference Reference
A 164 (38.7) 222 (45.7) 180 (40.9) 234 (57.6) 202 (37.1) 1.3 (1.1-1.6) 0.03 1.4 (1.1-1.9) 0.017 0.9 (0.7 - 1.2) 0.87 1.3 (0.9-1.8) 0.15
Dominant
CC 94 (44.3) 88 (36.2) 86 (39.1) 75 (36.9) 101 (37.1) Reference Reference Reference Reference
AC & AA 118 (55.7) 155 (63.8) 134 (60.9) 128 (63.1) 171 (62.9) 1.0 (0.7-1.3) 0.72 1.45 (0.9-2.2) 0.07 1.2 ( 0.8-1.8) 0.38 1.4 (0.8-2.3) 0.16
Recessive
CC & AC 166 (78.3) 176 (72.4) 174 (79.1) 159 (78.3) 241 (88.6) Reference Reference Reference Reference
AA 46 (21.7) 67 (27.6) 46 (20.9) 44 (21.7) 31 (11.4) 2.4 (1.6-3.7) <0.0001 1.5 (0.9-2.4) 0.08 0.9 (0.5-1.5) 0.61 1.2 (0.7-2.1) 0.47
Abbreviations: CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; HC: Healthy control;  
Cases = all HBV infected patients; n= Number of chromosomes; OR: adjusted Odd Ratio; ORs and P values were 
calculated by using binary logistic regression model adjusted for age and gender. P for trend was calculated by Cochran-
Armitage test. Bold values present the statistical significance.
LC and HCC in HBV patients. However, no significant 
difference was observed when haplotype frequencies of 
LC and HCC patients were compared.
SOCS3 promoter variants and clinical 
parameters
The HBV loads were lower in HBV patients with 
rs111033850CC compared to those with rs111033850TT 
and rs111033850TC (P=0.034). In contrast, viral loads 
were higher in HBV patients with rs12953258AA 
compared to those with rs12953258CC and rs12953258AC 
(P=0.029) (Figure 1A and 1C). To further examine this 
possible association, we compared HBV loads according 
to different genotypes for each SNP in the subgroups of 
HBV patients. A similar trend of HBV loads was observed 
in HCC+LC group for rs111033850 (P=0.045) and in LC 
group for rs12953258 (P=0.039) (Figure 1B and 1D). 
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Table 4: Association of SOCS3 haplotypes with HBV-related liver diseases
SOCS3
Haplotype 
HC CHB LC HCC HCC+LC Cases vs. HC LC vs. CHB HCC vs. CHB HCC+LC vs. CHB





























CC 92 (16.9) 24 (5.7) 42 (8.7) 46 (10.5) 46 (11.3)













Abbreviations: CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; HC: Healthy control;  
Cases = all HBV infected patients; n= Number of chromosomes; NA: not applicable; OR: Adjusted Odd Ratio; ORs and 
P values were calculated by using binary logistic regression model adjusted for age and gender. Bold values present the 
statistical significance.
Figure 1: Association of HBV loads with SOCS3 SNPs. A. and B. HBV viral loads according to different genotypes of SNP 
rs111033850T/C in all HBV patients and in patients with both liver cirrhosis and hepatocellular carcinoma, respectively. C. and D. HBV 
loads according to different genotypes of SNP rs12953258C/A in all HBV patients and in patients with liver cirrhosis, respectively. Box-
plots illustrate medians with 25 and 75 percentiles with whiskers to 10 and 90 percentiles; P values were calculated by Krusskal-Wallis test.
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However, there was no significant association of these 
SNPs with clinical parameters: ALT, AST, total and direct 
bilirubin, albumin, prothrombin, platelet counts and AFP 
(P>0.05) (Supplementary Figure 1 and 2). In addition, we 
also compared clinical parameters according to different 
haplotypes however we did not observe any significant 
association of SOCS3 promoter haplotypes with laboratory 
parameters.
Methylation status of SOCS3 promoter region in 
primary HCCs
In total, 127 CpG islands in the fragment of 1150 
bp (-1091 through +60) in the SOCS3 promoter region 
were investigated. We found that CpG islands were 
unmethylated in the fragment 1 (-1091 through -679) 
while were hypermethylated in the fragment 2 (-425 
through -217) and in the fragment 3 (-140 through 
-28) (Figure 2 and 3A). Subsequently, we analyzed 
methylation status in the SOCS3 promoter in 37 pairs 
of tissue samples (tumor and adjacent non-tumor 
tissues). We observed that the SOCS3 promoter region 
was methylated in 26/37 (70.3%) liver tumor tissues 
while only in 11/37 (29.7%) adjacent non-tumor tissues 
showed methylation patterns (OR=5.4, 95%CI=1.9-17.1, 
P=0.0011) (Figure 3A). This result indicates that SOCS3 
promoter methylation occurs more frequently in tumor 
tissues compared to adjacent non-tumor tissues. In 
addition, we analyzed the intensity of SOCS3 promoter 
methylation in 11 pairs of tissue samples, in which 
SOCS3 promoter methylation was detected in both 
tumor and adjacent non-tumor tissues. We observed that 
the methylation intensity was higher in tumor tissues 
compared to adjacent non-tumor tissues (P=0.012) 
(Figure 3B). In addition, we compared the status and 
intensity of SOCS3 promoter methylation between 
tissue samples (tumor and non-tumor) with and without 
HBV infection. However, no statistical significance was 
observed.
SOCS3 mRNA expression in primary HCCs
The mean levels of SOCS3 mRNA expression did 
not differ significantly between tumor and non-tumor 
tissues (Figure 4A and Supplementary Figure 3). The 
hypermethylated tumor tissues had significantly decreased 
SOCS3 mRNA expression than non hypermethylated 
tumor tissues (P=0.0023). However, there were no 
significant differences in SOCS3 mRNA expression 
between hypermethylated tumor and non-tumor liver 
tissues. (Figure 4B and Supplementary Figure 3). Our data 
demonstrate that the hypermethylation status in the SOCS3 
promoter is associated with downregulation of the SOCS3 
mRNA expression in tumor tissues.
SOCS3 mRNA expression discriminating between 
HCC and non-HCC tissue samples showed that SOCS3 
mRNA expression was significantly higher in HBV-related 
HCC tissues compared to non-HBV-related HCC tissues 
(P=0.0048) (Figure 4C and Supplementary Figure 3). 
In order to examine whether SOCS3 mRNA expression 
was associated with the development of liver cancer, 
we analyzed SOCS3 mRNA expression according to the 
BCLC staging classification. However, SOCS3 mRNA 
expression was not different between stage A and B HCC 
tissues (Figure 4D and Supplementary Figure 3).
DISCUSSION
The negative regulator SOCS3 is a key player in 
the modulation of the JAK/STAT signaling that control 
a number of inflammatory cytokines such as IL6 and 
IL16 [6] and is involved in infectious diseases and 
cancers [13, 14]. In addition, gene silencing mediated 
by aberrant methylation of CpG islands in the SOCS3 
promoter frequently occurs in malignancies [16, 21]. 
In this study, we investigated the possible association 
of SOCS3 promoter variants with the progression of 
HBV-related liver diseases and SOCS3 methylation 
with HBV-induced HCC. We showed that the SOCS3 
Figure 2: Schematic structure of SOCS3 gene presenting the location of CpG island. Methylation status of SOCS3 promoter 
region was analyzed by bisulfite sequencing (BS). The start codon site for SOCS3 gene is defined as +1. The shaded boxes depict the 
exons of the SOCS3 gene and open box represents the reported STAT3-binding site and the black boxes represent the region with aberrant 
methylation in the fragments 2 and 3.
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promoter variants are associated with HBV infection 
and HBV-related liver diseases. SOCS3 mRNA 
expression was higher in tumor tissues infected with 
HBV than non-infected tumor tissues. The aberrant 
methylation of the CpG islands in the SOCS3 promoter 
is associated with relatively low mRNA expression in 
tumor tissues.
This first study reports on the association of SOCS3 
variants with HBV susceptibility and progression of HBV-
related liver diseases. We have shown that the variants 
rs111033850T/C and rs12953258C/A are associated 
with HBV infection and the progression of HBV-related 
liver diseases. Particularly, the variant rs111033850T/C 
shows a heterozygous advantage in HBV susceptibility 
but might be a risk factor for the disease progression. 
The contribution of the minor allele rs111033850C to 
the increased risk of HCC in CHB patients is through 
the gene dose manner. In studies on hepatitis C, the 
rs4969170AA genotype was associated with antiviral 
IFN-α resistance with increased SOCS3 expression in 
HCV patients [14, 18]. The rs4969170A/G polymorphism 
was associated with HCV treatment-induced neutropenia 
Figure 3: Methylation status of the SOCS3 CpG islands in the promoter region. A. Methylation status of HCC tumor and 
non-tumor tissues. We randomly sequenced five to eight clones of PCR products amplified from Bisulfite treated genomic DNA for each 
liver tissue sample. The highly methylated CpG islands were found in two regions (from positions -425 to -217 and from positions -140 
to -28). Each square shape presents one CpG island, black color shows CpG islands with methylation and white color shows CpG islands 
without methylation. B. Methylation intensity of the 11 HCC tumor and 11 adjacent non-tumor tissue samples. P values were calculated 
by Mann-Whitney test.
Oncotarget9www.impactjournals.com/oncotarget
and thrombocytopenia in antiviral therapy with pegylated 
interferon alpha [17]. The rs4969170A/G polymorphism 
was associated with clinical features and prognosis of 
HCC after surgical treatment [22]. Our results support 
earlier findings that SOCS3 polymorphisms influence 
liver disease progression by modulating the SOCS3 
protein expression and thus down-regulate the JAK/STAT 
signaling.
In this study, we showed that HBV-DNA loads were 
associated with the SOCS3 promoter polymorphisms 
rs111033850T/C and rs12953258C/A. The HBV-DNA 
loads are an important and independent risk factor for 
liver disease progression in CHB patients [23, 24]. The 
effects of HBV replication during HBV persistence were 
regulated by many host factors [25]. Previous studies have 
shown that the control of HBV replication was regulated 
by JAK/STAT signaling, which is activated by IFNs 
[15, 26, 27]. IFNs play a central role in control of viral 
replication including HBV [28] and IFNs are controlled 
by JAK/STAT signaling, which is regulated by SOCS3 
protein [9]. Therefore, SOCS3 promoter variants might 
have contributed to control of HBV replication through 
IFN signaling, which is also regulated by JAK/STAT 
signaling. However, the effects of SOCS3 and its variants 
on the cytokine signaling that subsequently influence the 
HBV replication are required further studies.
Cytokines are involved in cell communication and 
are required for the defense against hepatitis viruses [28]. 
Previous study has shown that the HCV core protein 
impairs IFN-α-induced signal transduction via induction 
of SOCS3 expression [29] and therefore influences 
the outcome of antiviral therapy [30]. SOCS3 was 
Figure 4: Expression of SOCS3 mRNA in liver specimens from HCC patients. Quantitative real-time PCR (qRT-PCR) 
analysis presents comparison of SOSC3 mRNA level. A. The SOSC3 mRNA level in the tumor tissues and adjacent non-tumor tissues. 
B. The SOSC3 mRNA level in the tumor and in non-tumor tissues with methylation (M) and in the tumor and in non-tumore tissues with 
un-methylation (UM). C. The SOSC3 mRNA level in patients positive for HBV and in patients negative for both HBV and HCV. D. The 
SOSC3 mRNA level in patients at early HCC stage (Stage A) and in patients at intermediate HCC stage (Stage B). The GAPDH gene was 
used as a reference gene. The data are shown as the medians with inter-quartile range. P values were calculated by Mann-Whitney test.
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overexpressed in liver tissues and was strongly associated 
with severity of hepatic inflammation in CHB patients [15, 
27]. In accordance, SOCS3 overexpression was observed 
in liver tissues from HBV-infected patients rather than 
non-HBV patients. These results may indicate that HBV 
can induce SOCS3 expression, which in turn inhibits IFN 
signaling transduction resulting in the progression of liver 
diseases and failure of IFN treatment of HBV infection 
[27].
HCC development is often due to chronic liver 
injury, inflammation, and cirrhosis caused by the 
persistence of HBV infection. However, the interaction 
between HBV and SOCS3 in infected hepatocytes has not 
been clearly understood. DNA hypermethylation in the 
promoter region can lead to the silence of SOCS3 in HCC 
[16, 31]. SOCS3 silencing by promoter methylation is 
possibly involved in the progression of HBV-related liver 
cancer. In line with previous studies, our results showed 
that aberrant methylation in the SOCS3 promoter region 
was observed more frequently in tumor tissues compared 
to adjacent non-tumor tissues. Hypermethylation status 
in the SOCS3 promoter region may be a crucial factor 
for HCC development. However, SOCS3 expression 
in tumor and adjacent non-tumor tissues was not 
significantly different, suggesting that other factors such 
as phosphorylation, acetylation and microRNAs may also 
involve in the regulation of SOCS3 expression during 
progression of liver diseases [32]. In addition, both SOCS3 
methylation status and intensity were not significantly 
different between tissue samples (tumor and non-tumor) 
from patients with and without HBV infection. This 
indicates that HBV may not promote DNA methylation 
of host genes in infected hepatocytes. However, further 
studies are needed to verify this preliminary observation 
since the number of samples used for this analysis was 
rather small.
Although our data indicate that SOCS3 expression 
is associated with HBV infection and may involve in the 
progression of HBV-related liver diseases, the study has 
several limitations. A limited number of HCC tumor and 
non-tumor tissues were utilized. Due to the study design 
as a case-control study, SOCS3 expression over the 
course of HBV infection were not assessed longitudinally 
and therefore the causative effect of SOCS3 expression 
on progression of HBV-related liver diseases could not 
conclusively be determined. The insufficiency of some 
clinical and laboratory parameters such as HBV serology 
tests and HBV genotypes may weaken the findings 
indicating the crucial role of SOCS3 in the immune 
response to HBV infection and the disease outcomes.
In conclusion, the SOCS3 promoter variants 
rs111033850 and rs12953258 are associated with 
HBV infection and HBV-related liver diseases. DNA 
methylation in the SOCS3 promoter region is related to the 
regulation of SOCS3 expression and occurs frequently in 
HCC tumors of HBV-infected patients. Our study suggests 
that SOCS3 polymorphisms and methylation play an 
important role in regulation of SOCS3 expression and thus 
influences the progression of HBV-related liver diseases.
MATERIALS AND METHODS
Patients and liver specimens
878 unrelated Vietnamese HBV-infected patients 
were randomly recruited in a case-control design at 108 
Military Central Hospital and 103 Military Hospital 
of the Vietnam Military Medical University, Hanoi, 
Vietnam, between 2012 and 2013. With this sample size, 
we can detect the significance of common studied SOCS3 
variants according to the sample size estimation based on 
the 95% confidence interval, the lowest detection rate of 
minor allele set at the lowest value of 5%, a significance 
level of 5% and a power >90%. Patients were assigned 
to subgroups of disease based on clinical manifestations 
and liver function tests. Subgroups included chronic 
hepatitis (CHB, n=212), liver cirrhosis (LC, n=243), 
hepatocellular carcinoma (HCC, n=220) and patients 
with LC and HCC (LC+HCC, n=203). The diagnostic 
criteria for the CHB patients and the HBV-related LC 
were previously described [33]. The HBV-related HCC 
group was characterized as patients infected with HBV 
and was diagnosed based on the American Association 
for the Study of Liver Diseases (AASLD) practice 
guideline for HCC [34]. The patients with LC and 
HCC were characterized if the patients showed clinical 
manifestations and laboratory tests of both LC and HCC. 
The patients with LC were also categorized as Child-A, 
Child-B and Child-C based on Child-Pugh scores [35]. 
None of these HBV-infected patients had a history of 
alcohol or drug abuse. All participants were confirmed 
negative for anti-HCV and anti-HIV by ELISA assays. 
HBV-DNA loads and liver function tests including alanine 
transaminase (ALT), aspartate transaminase (AST), total 
bilirubin and direct bilirubin, albumin, prothrombin were 
quantified. 272 blood samples from healthy individuals 
were collected from blood bank as the control group. In 
addition, we analyzed 37 dyads of liver specimens (tumor 
and adjacent non-tumor) collected from HCC patients 
who underwent surgery at the 108 Military Central 
Hospital between 2013 and 2014. The HCC patients who 
underwent surgery were independent from 878 HBV 
patients. HCC was confirmed by histology and classified 
based on the BCLC classification [36]. All specimens 
were frozen at -80°C until use.
Ethics statement
Informed written consent was obtained after 
explanation of the study at the time of sampling from all 
participants. The study was approved by the institutional 
review board of the 108 Military Central Hospital and the 
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103 Military Hospital of the Vietnam Military Medical 
University, Hanoi, Vietnam.
Genotyping of SOCS3 promoter variants
Genomic DNA was isolated from blood using DNA 
purification kits (Qiagen, Hilden, Germany). The SOCS3 
promoter region (nucleotides -1109 to -772) including 
two pre-described SNPs (rs111033850 and rs12953258) 
were amplified by PCR using primer pair SOCS3_PrF and 
SOCS3_PrR (Supplementary Table 1). PCR components, 
thermal conditions and sequencing procedures are 
presented in the Supplementary Materials.
SOCS3 promoter methylation analysis
Liver tissues were grounded using liquid nitrogen. 
Genomic DNA was extracted from liver powder using 
DNA purification kit (Qiagen, Hilden, Germany). 
Extracted DNA (2μg) was subjected to bisulfite 
conversion using EZ DNA Methylation-Direct™ Kit 
(Zymo Research Corp, the USA), according to the 
manufacturer’s protocol. Three different fragments were 
amplified from bisulfite-treated genomic DNA using three 
specific primer sets (Figure 2 and Supplementary Table 1). 
The PCR products were subsequently cloned into TOPO-
TA pCR2.1 vector (Life Technologies, the USA). Eight 
clones were randomly picked from each transformation 
(each tissue sample) and were analyzed for methylation 
by direct sequencing.
SOCS3 mRNA expression
Total RNA was extracted from 37 dyads of liver 
biopsy tissues with Trizol reagent (Life Technologies, 
the USA). RNA was reverse transcribed into cDNA using 
QuantiTect Reverse Transcription Kit (Qiagen GmbH, 
Hilden, Germany). cDNA quantification was performed 
by qRT-PCR and GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) gene was used as a reference gene. 
The specific primers used for evaluating SOCS3 mRNA 
expression as well as the PCR components and thermal 
conditions of qRT-PCR are presented in the Supplementary 
Materials. Calculation of normalized gene expression was 
based upon the ΔΔCT method.
Statistical and genetic analysis
All statistical analysis was performed using R 
version 3.1.2 (http://www.r-project.org) and GraphPad 
Prism 6 (http://www.graphpad.com). Genotype and allelic 
frequencies were determined by simple gene counting 
and the haplotype frequency was estimated using the 
expectation-maximum algorithm method implemented 
in the Arlequin v.3.5.2.2. The deviations from Hardy-
Weinberg equilibrium were calculated for each group. 
We used a binary logistic regression adjusted for age 
and gender to analyze association of SOCS3 variants 
with HBV-related liver diseases applying for different 
genetic models. In the binary logistic regression model, 
the disease subgroups and control group are considered 
as dependent variables. The genetic data are considered 
as independent variables (predictors) while age (treated 
as a continuous variable) and gender (treated as a binary 
variable) are independent confounding factors. In addition, 
the Cochran-Armitage test for trend was used to examine 
the gene dose effect of risk allele. Fisher’s exact test 
was used to test the difference of categorical variables 
between two groups. Student's t-test and Mann Whitney 
Wilcoxon test were used to compare the parametric and 
non-parametric data of quantitative variables between 
two groups, respectively. Kruskal-Wallis test was used 
to compare non-parametric data of quantitative variables 
among more than two groups. The level of significance 
was set at a value of P< 0.05.
Abbreviations
CHB, chronic hepatitis B; HBV, hepatitis B virus; 
HC, healthy control; HCC, hepatocellular carcinoma; LC, 
liver cirrhosis; SNP, single nucleotide polymorphism; 
SOCS3, suppressor of cytokine signaling-3.
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